PHILADELPHIA — New research presented today at the 2013 Scientific Sessions of the American Heart Association by researchers at the Perelman School of Medicine at the University of Pennsylvania found no difference in outcomes at one-year between two recommended surgical options for treating ischemic mitral regurgitation (IMR) – repair of the leaky valve or its replacement with an artificial valve. The study, conducted by the Cardiothoracic Surgical Trials Network (CTSN), a consortium supported by the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS) of the National Institute of Health, along with the Canadian Institutes of Health Research (CIHR), was published simultaneously in the New England Journal of Medicine.
Mitral regurgitation – where blood flows backwards toward the lungs during the contraction of the heart instead of forwards – affects millions of people in the U.S. and can pose serious health consequences, most prominently ongoing and worsening heart failure. Guidelines currently recommend either repair or replacement of severe mitral leak caused by ischemic mitral insufficiency when medical alternatives have failed.
“While the medical community has traditionally gravitated towards valve repair as a preferred treatment option, the evidence in this study does not suggest that mitral valve repair is superior,” said lead study author Michael Acker, MD, chief, Division of Cardiovascular Surgery and director, Penn Medicine Heart and Vascular Center. “Further patient follow-up is needed to confirm the findings of this trial, but we believe these results should be very helpful for cardiologists and surgeons in choosing an appropriate approach for this growing patient population.”
This multi-center study, the Severe MR randomized trial (of which cardiac surgeons at Penn were the leading enrollers), is the first randomized clinical trial comparing these two options to treat IMR. Both approaches offer benefits and risks, but as of yet no study has rigorously evaluated these approaches to see if the trade-offs result in significant differences in patient outcomes.
The study enrolled 251 patients who were diagnosed with IMR, which is due to a valve deformation that occurs after a heart attack. The participants were evenly randomized to receive either surgical repair (a valve tightening procedure called an annuloplasty) or a prosthetic replacement mitral valve.
The participants were then monitored at one, six, and 12 months after their procedure. The primary endpoint of the study was the degree of left ventricular shrinkage (reverse remodeling) which correlates to improvement in heart function and the lessening of heart failure symptoms. The study also measured various health outcomes, including rates of death, recurrent mitral valve leak, severe heart problems or stroke, re-hospitalizations, and quality of life.
After a year a follow-up, there were almost no differences in ventricle shrinkage or health between the two treatments. The only significant change was a higher rate of recurrent regurgitation in the repair group (32.6 percent of repair patients versus 2.3 percent of replacement patients).
“The increased level of recurrent regurgitation falls in line with valve replacement offering more durable long-term protection,” noted Annetine Gelijns, Ph.D., CTSN investigator at the Icahn School of Medicine at Mount Sinai and corresponding author of the study. “However, these regurgitations did not lead to any noticeable increases of health problems among patients in the repair group.”
The study investigators will continue to monitor the participants for 12 more month, as well as an analysis of predictors of recurrent mitral valve leak, which may help identify patient groups better suited for repair or replacement.
In addition to Penn, the study was carried out at 21 participating CTSN centers across the United States and Canada.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report‘s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania — recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital — the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.